Table 1.
Treatment planning guidelines and achieved dosimetry
| Structure | Volume | Goal | Median delivered (range) |
|---|---|---|---|
| Prostate PTV | % receiving 34.44 Gy | 100% | 100% |
| % receiving 36.25 Gy | Not Specified | 95.1% (43.3%-99.9%) | |
| Prostate | Dose to 99% | Not Specified | 36.3 Gy (35.0-37.0) |
| Boost PTV | % receiving 38 Gy | >95% | 100% (97%-100%) |
| % receiving 40 Gy | Not Specified | 88% (50.2%-100%) | |
| Rectum | Maximum dose to 1 cm3 | ≤38.06 Gy | 35.7 Gy (34.2-36.6) |
| Maximum dose to 3 cm3 | <34.4 Gy | 33.96 Gy (31.57-34.39) | |
| % receiving 36.25 Gy | <5% | 0.7% (0.03%-3.91%) | |
| % receiving 29 Gy | <20% | 11.8% (6.74%-17.91%) | |
| % receiving 18.125 Gy | <50% | 36.98% (23.16%-49.9%) | |
| Bladder | Maximum dose to 1 cm3 | ≤38.06 Gy | 37.5 Gy (36.31-38.06) |
| % receiving 32.625 Gy | <10% | 3.86% (0.96%-8.97%) | |
| % receiving 18.125 Gy | <50% | 14.84% (2.63%-40.29%) | |
| Urethra | Maximum point dose | ≤38.78 Gy | 38.51 Gy (36.57-38.78) |
| Femoral heads | Maximum point dose | 30 Gy | 13.61 Gy (11.12-18.7) |
| Maximum dose to 10 cm3 (both sides) | 20 Gy | 9.9 Gy (7.95-13.97) | |
| Body | Maximum point dose | Not Specified | 41.91 Gy (40.26-45.81) |
Abbreviation: PTV = planning target volume.